Literature DB >> 11902815

Progress in the development of immunotherapy for the treatment of patients with cancer.

S A Rosenberg1.   

Abstract

Several recent developments have hallmarked progress in tumour immunology and immunotherapy. The use of interleukin-2 (IL-2) in cancer patients demonstrated that an immunological manipulation was capable of mediating the regression of established growing cancers in humans. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing patients against these antigens has opened important new avenues of exploration for the development of effective active and cell-transfer immunotherapies for patients with cancer.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11902815      PMCID： PMC2413437          DOI： 10.1046/j.1365-2796.2001.00911.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN： 0954-6820            Impact factor:   8.989


  67 in total

1.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

2.  In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens.

Authors:  S A Rosenberg; S Schwarz; P J Spiess
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

3.  Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.

Authors:  Y Kawakami; X Wang; T Shofuda; H Sumimoto; J Tupesis; E Fitzgerald; S Rosenberg
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

4.  Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.

Authors:  M Harada; Y F Li; M El-Gamil; S A Rosenberg; P F Robbins
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

5.  T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.

Authors:  M E Dudley; L T Ngo; J Westwood; J R Wunderlich; S A Rosenberg
Journal:  Cancer J       Date:  2000 Mar-Apr       Impact factor: 3.360

6.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

Authors:  M T Lotze; E A Grimm; A Mazumder; J L Strausser; S A Rosenberg
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

7.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

8.  In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens.

Authors:  J L Strausser; S A Rosenberg
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

9.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307
View more
  32 in total

1.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

2.  Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera.

Authors:  Soung-Chul Cha; Larry W Kwak; Pier Adelchi Ruffini; Hong Qin; Sattva Neelapu; Arya Biragyn
Journal:  J Immunol Methods       Date:  2006-03-31       Impact factor: 2.303

3.  CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.

Authors:  Karen Brajão de Oliveira; Roberta Losi Guembarovski; Alda Maria Fiorina Losi Guembarovski; Ana Cristina da Silva do Amaral Herrera; Walter Jorge Sobrinho; Carolina Batista Ariza; Maria Angelica Ehara Watanabe
Journal:  Clin Exp Med       Date:  2012-06-15       Impact factor: 3.984

4.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

5.  Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.

Authors:  Juhua Zhou; Mark E Dudley; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2005 Jan-Feb       Impact factor: 4.456

6.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

7.  Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.

Authors:  Qing-Guo Fu; Fan-Dong Meng; Xiao-Dong Shen; Ren-Xuan Guo
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

8.  Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.

Authors:  Luca Degrate; Cinzia Nobili; Claudio Franciosi; Roberto Caprotti; Fernando Brivio; Fabrizio Romano; Biagio Eugenio Leone; Rosangela Trezzi; Franco Uggeri
Journal:  Langenbecks Arch Surg       Date:  2008-08-01       Impact factor: 3.445

Review 9.  Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.

Authors:  Yuzuru Ikehara; Masahiro Yamanaka; Takashi Yamaguchi
Journal:  J Biomed Biotechnol       Date:  2010-06-17

10.  Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.

Authors:  Shannon P Hilchey; James J Kobie; Mathew R Cochran; Shelley Secor-Socha; Jyh-Chiang E Wang; Ollivier Hyrien; W Richard Burack; Tim R Mosmann; Sally A Quataert; Steven H Bernstein
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.